Systemic expression of matrix metalloproteinase-9 in patients with cerebral arteriovenous malformations

Neurosurgery

Volumn 66, Issue 2, 2010, Pages 343-348

  Starke, Robert M ^a   Komotar, Ricardo J ^b   Hwang, Brian Y ^b   Hahn, David K ^c   Otten, Marc L ^b   Hickman, Zachary L ^b   Garrett, Matthew C ^b   Sisti, Michael B ^b   Lavine, Sean D ^b   Meyers, Philip M ^b   Solomon, Robert A ^b   Connolly, E Sander ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Angiogenesis; Arteriovenous malformation; Matrix metalloproteinase; Systemic; Vascular disease

Indexed keywords

GELATINASE B;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BRAIN ARTERIOVENOUS MALFORMATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; ARTERIOVENOUS FISTULA; EMBOLIZATION, THERAPEUTIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; RETROSPECTIVE STUDIES; STATISTICS AS TOPIC; TIME FACTORS; YOUNG ADULT;

EID: 75749101027     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000363599.72318.BA     Document Type: Article

References (40)

1. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;274(31): 21491-21494.
2. Lukes A, Mun-Bryce S, Lukes M, Rosenberg GA. Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Mol Neurobiol. 1999;19(3):267-284.
3. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia. 2002;39(3): 279-291.
4. Kuroiwa T, Ting P, Martinez H, Klatzo I. The biphasic opening of the blood-brain barrier to proteins following temporary middle cerebral artery occlusion. Acta Neuropathol. 1985;68(2):122-129.
5. Sood RR, Taheri S, Candelario-Jalil E, Estrada EY, Rosenberg GA. Early beneficial effect of matrix metalloproteinase inhibition on blood-brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain. J Cereb Blood Flow Metab. 2008;28(2)431-438.
6. Alvarez-Sabín J, Delgado P, Abilleira S, et al. Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome. Stroke. 2004;35(6):1316-1322.
7. Axisa B, Loftus IM, Naylor AR, et al. Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke. 2002;33(12):2858-2864.
8. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2(10):737-744.
9. Chiappori AA, Eckhardt SG, Bukowski R, et al. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res. 2007;13(7):2091-2099.
10. Gijbels K, Galardy RE, Steinman L. Reversal of experimental autoimmune encepha-lomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest. 1994;94(6):2177-2182.
11. Gu Z, Cui J, Brown S, et al. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci. 2005;25(27):6401-6408.
12. Hashimoto T, Matsumoto MM, Li JF, Lawton MT, Young WL; University of California, San Francisco, BAVM Study Group. Suppression of MMP-9 by doxycycline in brain arteriovenous malformations. BMC Neurol. 2005;5(1):1.
13. Hashimoto T, Wen G, Lawton MT, et al. Abnormal expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in brain arteriovenous malformations. Stroke. 2003;34(4):925-931.
14. Hovsepian DM, Ziporin SJ, Sakurai MK, Lee JK, Curci JA, Thompson RW. Elevated plasma levels of matrix metalloproteinase-9 in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease. J Vasc Interv Radiol. 2000;11(10):1345-1352.
15. Kim SC, Singh M, Huang J, et al. Matrix metalloproteinase-9 in cerebral aneurysms. Neurosurgery. 1997;41(3):642-667.
16. Leib SL, Clements JM, Lindberg RL, et al. Inhibition of matrix metalloproteinases and tumour necrosis factor converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain. 2001;124(Pt 9):1734-1742.
17. Lorelli DR, Jean-Claude JM, Fox CJ, et al. Response of plasma matrix metalloproteinase-9 to conventional abdominal aortic aneurysm repair or endovascular exclusion: implications for endoleak. J Vasc Surg. 2002;35(5):916-922.
18. McMillan WD, Pearce WH. Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. J Vasc Surg. 1999;29(1):122-129.
19. Montaner J, Alvarez-Sabín J, Molina C, et al. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke. 2001;32(8):1759-1766.
20. Pfefferkorn T, Rosenberg GA. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke. 2003;34(8):2025-2030.
21. Rosenberg GA. Growth and bleeding in BAVM: another role for MMPs. Stroke. 2003;34(4):925-931.
22. Rosenberg GA, Dencoff JE, Correa N Jr, Reiners M, Ford CC. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology. 1996;46(6):1626-1632.
23. Sangiorgi G, D'Averio R, Mauriello A, et al. Plasma levels of metalloproteinases-3 and-9 as markers of successful abdominal aortic aneurysm exclusion after endovascular graft treatment. Circulation. 2001;104 [Suppl 1](12):I288-I295.
24. Watanabe T, Sato A, Sawai T, et al. The elevated level of circulating matrix metalloproteinase-9 in patients with abdominal aortic aneurysms decreased to levels equal to those of healthy controls after an aortic repair. Ann Vasc Surg. 2006;20(3):317-321.
25. Lee CZ, Xue Z, Zhu Y, Yang GY, Young WL. Matrix metalloproteinase-9 inhibition attenuates vascular endothelial growth factor-induced intracerebral hemorrhage. Stroke. 2007;38(9):2563-2568.
26. Lee CZ, Yao JS, Huang Y, et al. Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J Cereb Blood Flow Metab. 2006;26(9):1157-1164.
27. Yao JS, Shen F, Young WL, Yang GY. Comparison of doxycycline and minocycline in the inhibition of VEGF-induced smooth muscle cell migration. Neurochem Int. 2007;50(3):524-530.
28. Chen Y, Fan Y, Poon KY, et al. MMP-9 expression is associated with leukocytic but not endothelial markers in brain arteriovenous malformations. Front Biosci. 2006;11:3121-3128.
29. Hashimoto T, Wu Y, Lawton MT, Yang GY, Barbaro NM, Young WL. Coexpression of angiogenic factors in brain arteriovenous malformations. Neurosurgery. 2005;56(5): 1058-1065. (Pubitemid 40628114)
30. Lee CZ, Xu B, Hashimoto T, McCulloch CE, Yang GY, Young WL. Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model. Stroke. 2004;35(7):1715-1719.
31. Yao JS, Chen Y, Zhai W, Xu K, Young WL, Yang GY. Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration: the role of ERK1/2, PI3K, and matrix metalloproteinases. Circ Res. 2004;95(4):364-371.
32. Hashimoto G, Inoki I, Fujii Y, Aoki T, Ikeda E, Okada Y. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem. 2002;277(39):36288-36295.
33. Kim GH, Hahn DK, Kellner CP, et al. Plasma levels of vascular endothelial growth factor after treatment for cerebral arteriovenous malformations. Stroke. 2008;39(8): 2274-2279.
34. Koizumi T, Shiraishi T, Hagihara N, Tabuchi K, Hayashi T, Kawano T. Expression of vascular endothelial growth factors and their receptors in and around intracranial arteriovenous malformations. Neurosurgery. 2002;50(1):117-126.
35. Gerlach RF, Demacq C, Jung K, Tanus-Santos JE. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem. 2007;40(1-2):119-123.
36. Montaner J, Alvarez-Sabín J, Molina CA, et al. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke. 2001;32(12):2762-2767. (Pubitemid 33134461)
37. Kim GH, Hahn DK, Kellner CP, et al. Plasma levels of vascular endothelial growth factor after treatment for cerebral arteriovenous malformations. Stroke. 2008;39(8): 2274-2279.
38. Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003;107(4):598-603.
39. Rosell A, Alvarez-Sabín J, Arenillas JF, et al. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusionweighted image lesion increase in human stroke. Stroke. 2005;36(7):1415-1420.
40. Rosell A, Ortega-Aznar A, Alvarez-Sabín J, et al. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke. 2006;37(6):1399-1406.